1887
  1. Home
  2. Eurosurveillance
  3. Volume 27, Issue 39, 29/Sep/2022
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

We assess the immunogenicity and efficacy of Spikevax and Comirnaty as fourth dose COVID-19 vaccines. Six months post-fourth-dose, IgG levels were higher than pre-fourth dose at 1.58-fold (95% CI: 1.27–1.97) in Spikevax and 1.16-fold (95% CI: 0.98–1.37) in Comirnaty vaccinees. Nearly 60% (159/274) of vaccinees contracted SARS-CoV-2. Infection hazard ratios (HRs) for Spikevax (0.82; 95% CI: 0.62–1.09) and Comirnaty (0.86; 95% CI: 0.65–1.13) vaccinees were similar, as were substantial-disease HRs, i.e. 0.28 (95% CI: 0.13–0.62) and 0.51 (95% CI: 0.27–0.96), respectively.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.39.2200701
2022-09-29
2024-12-22
/content/10.2807/1560-7917.ES.2022.27.39.2200701
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/39/eurosurv-27-39-1.html?itemId=/content/10.2807/1560-7917.ES.2022.27.39.2200701&mimeType=html&fmt=ahah

References

  1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. , C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.  https://doi.org/10.1056/NEJMoa2034577  PMID: 33301246 
  2. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. , COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-16.  https://doi.org/10.1056/NEJMoa2035389  PMID: 33378609 
  3. Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, et al. Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron. N Engl J Med. 2022;386(14):1377-80.  https://doi.org/10.1056/NEJMc2202542  PMID: 35297591 
  4. Canetti M, Barda N, Gilboa M, Indenbaum V, Mandelboim M, Gonen T, et al. Immune Response and Clinical Outcomes of BNT162b2 and mRNA1273 Fourth Dose COVID-19 Vaccines; Three Months Follow-up. Research Square2022Aug11 https://doi.org/10.21203/rs.3.rs-1946528/v1 
  5. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2020. Available from: https://www.R-project.org/
  6. Lustig Y, Sapir E, Regev-Yochay G, Cohen C, Fluss R, Olmer L, et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med. 2021;9(9):999-1009.  https://doi.org/10.1016/S2213-2600(21)00220-4  PMID: 34224675 
  7. Lustig Y, Gonen T, Meltzer L, Gilboa M, Indenbaum V, Cohen C, et al. Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose. Nat Immunol. 2022;23(6):940-6.  https://doi.org/10.1038/s41590-022-01212-3  PMID: 35534723 
  8. Chu L, Vrbicky K, Montefiori D, Huang W, Nestorova B, Chang Y, et al. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nat Med. 2022;28(5):1042-9.  https://doi.org/10.1038/s41591-022-01739-w  PMID: 35241844 
  9. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819-29.  https://doi.org/10.1016/S0140-6736(21)00947-8  PMID: 33964222 
  10. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093-100.  https://doi.org/10.1016/S0140-6736(21)02249-2  PMID: 34756184 
  11. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022;28(5):1063-71.  https://doi.org/10.1038/s41591-022-01753-y  PMID: 35189624 
  12. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med. 2021;385(24):e84.  https://doi.org/10.1056/NEJMoa2114583  PMID: 34614326 
  13. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):255-63.  https://doi.org/10.15585/mmwr.mm7107e2  PMID: 35176007 
  14. Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021;398(10317):2126-8.  https://doi.org/10.1016/S0140-6736(21)02758-6  PMID: 34871545 
Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Noam+Barda&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Barda Noam</a>, <a href="/search?value1=Michal+Canetti&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Canetti Michal</a>, <a href="/search?value1=Mayan+Gilboa&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Gilboa Mayan</a>, <a href="/search?value1=Victoria+Indenboim&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Indenboim Victoria</a>, <a href="/search?value1=Keren+Asraf&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Asraf Keren</a>, <a href="/search?value1=Yael+Weiss-Ottolenghi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Weiss-Ottolenghi Yael</a>, <a href="/search?value1=Sharon+Amit&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Amit Sharon</a>, <a href="/search?value1=Daniel+Zibly&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Zibly Daniel</a>, <a href="/search?value1=Ram+Doolman&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Doolman Ram</a>, <a href="/search?value1=Ella+Mendelson&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mendelson Ella</a>, <a href="/search?value1=Dror+Harats&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Harats Dror</a>, <a href="/search?value1=Laurence+S.+Freedman&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Freedman Laurence S.</a>, <a href="/search?value1=Yitshak+Kreiss&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kreiss Yitshak</a>, <a href="/search?value1=Yaniv+Lustig&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lustig Yaniv</a>, <a href="/search?value1=Gili+Regev-Yochay&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Regev-Yochay Gili</a></span>. Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022. <a href="/content/ecdc">Euro Surveill.</a> 2022;27(39):pii=2200701. <a href="https://doi.org/10.2807/1560-7917.ES.2022.27.39.2200701" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2022.27.39.2200701</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 05 Sept 2022;&nbsp;&nbsp; <span class="generated">Accepted</span>: 29 Sept 2022 </span> </p>
/content/10.2807/1560-7917.ES.2022.27.39.2200701
/content/10.2807/1560-7917.ES.2022.27.39.2200701
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error